Sheet

PTO/S8/08A (09-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT BY & TRADE (use as many sheets as necessary)

of

3

Complete if Known					
Application Number	10/071032				
Filing Date	February 8, 2002				
First Named Inventor	Richard Dennis Dyer, et al				
Group Art Unit	Unknown				
Examiner Name	. Unknown				
Attorney Docket Number	A0000425-01-CFP				

	U.S. PATENT DOCUMENTS							
Examiner Initials	Cts No.1	Marine Company	Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Clad Document MM-DD-YYYY	Pages, Cotumns, Lines, Where Rolevant Passages or Relevant Figurys Appear		
TVT	V.	5,082,838		Naka, et al	01/21/1992	514/2/1.1		
	V.	5.817.819		Furuya, et al	10/06/1998	546/114		
		5.948.780		Peterson, Jr., et al	09/07/1999	5141255		
TNI	1	6.008.243		Bender, et al	12/28/1999	514/422		
						· · · · · · · · · · · · · · · · · · ·		
			Ш					
			1_1					
			1		<u> </u>			
			\vdash					
			-		 			
			╀╌┤		 			
	-		╂╾┨					
			╁	:-:				
-			+					
			+		1			
			\vdash		1			
					†			
			1	······································				

					. FOR	EIGN PATENT DOCUMENT:	3	· · · · · · · · · · · · · · · · · · ·	
Examir Initials		Cite No.1	Office	Foreign Patent Docum Number ⁴	ient IGnd Code ^a (# known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Pessages or Relevant Figures Appear	Te
77	ণা	//	WO	95/35296		Takatani, et al	12/28/1995		•
\Box	T	V	wa	01/63244 A1		Chen, et al	08/30/2001		Т
\Box	7	V	EP	0 404 525 B1		Naka, et al	05/15/1996		T
	7	V	GB	2 097 396 A		Seivaku, et al	11/03/1982	•	
	Т	1/1	DE	41 37 437 A1		Furrer, et al	05/19/1993		
IV)	4	Z	EP	0 404 525 A		Naka. et al	12/27/1990		4_
	+								F
	+								

Examiner Signature	Mon	Date Considered	u	16/04	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 2 Enter Office that issued the document, by the two-latter code (WIPO Standard ST.3). * For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the sarial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

				_	$\overline{}$
Please type	a ptus sign (*	•) inside this	pæ	-	+

Proserved for use through 10/31/2002, OMB 0551-0031

U. S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 14498/PTO 10/071032 **Application Number** NFORMATION DISCLOSURE February 8, 2002 Filing Date Richard Dennis Dyer, et.al STATEMENT BY APPLICANT First Named Inventor Unknown Group Art Unit Unknown **Examiner Name** (use as many sheets as necessary) **Attorney Docket Number** A0000425-01-CFP Sheet 2 of 3

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
M	1	MONTANA, John, et al, "The design of selective non-substrate-based matrix metalloproteinase inhibitors", Current Opinion in Drug Discovery & Development, 2000; 3(4), pp 353-361,	
,	/	CLARK, lan, et al, "Matrix metalloproteinase inhibitors in the treatment of arthritis", Current Opinions in Anti-inflammatory & Immunomodulatory Investigational Drugs, 2000; 2(1), pp 16-25 -	
	/	CHEN, James, et al, "Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design", J. Am. Chem. Soc., 2000, 122; pp 9648-9654	
	/	DERWENT ABSTRACT, 96-068630/07, "New fused imidazole cpds possess inhibitory activity of adhesion molecule expression (Eng.)"	
	V	DERWENT ABSTRACT, 93-168431/21, "New Thiazolo-pyrimidine disone derivs. for treating anteriosclerosis"	
	1	DERWENT ABSTRACT, 91-001547/01, "New sulphur-Contg. fused pyrimidine cpds are endothelin and interleukin inhibitors for treatment and prevention of myocardial infarction, auto:immune diseases, etc."	
	1	DERWENT ABSTRACT, 93271 E/44, "Cyclised pro-form of 5-flouro-uracil derivs are orally administered antitumour agents without side effects of parent"	
	1	KAUL, Ravinder, et al, "2-14C-1-Allyl-3,5-diethyl-6-chlorouracil II: Isolation and Structures of the Major Sulfur-Free and Three Minor Sulfur-Containing Metabolites and Mechanism of Biotransformation", Journal of Pharmaceutical Sciences, Vol. 71, No. 8, August 1982; pp 897-900	
	1	KAUL, Ravinder, et al, "Structure of a novel sulphur-containing metabolite of Acluracil (1-ally1-3,5-diethyl-6-chlorouracil)", Xenobiotica, 1982, Vol. 12, No. 8; pp 495-498	
	V	KAUL, Von R., et al, "Identfizierung eines dritten S-haltigen Metaboliten von 1-Allyl-3,5-diethyl-6-chloruracil und Bildungsmechanismus der SCH - Metaboliten", ArzneimForsch/Drug Res., 1982; 32(I)(6); pp 610-612 •	
M	V	BROWN, et al, "The Synthesis of Some 1-Substituted Cytosine and Uracil Derivatives", J. Chem. Soc., 1972; pp 2385-2391	

Examiner Signature	Mom	Date Considered	1) 16/04

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Tredemark Office, Washington, OC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, OC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Pisase type a plus sign (+) inside this box	•	+

3

of

3

heet

A0000425-01-CFP

Pitasse type a plus sign (+) inside this box — + + Approved for use through 10/31/2002, OMB 0631-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwark Reduction Act of 1995, no persons are required to respond to a coffection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449B/PTO 10/071032 **Application Number** INFORMATION DISCLOSURE February 8, 2002 Filing Date Richard Dennis Dyer, et al STATEMENT BY APPLICANT First Named Inventor Unknown JUN 0 7 200 Group Art Unit Unknown Examiner Name (use as many sheets as necessary)

Attorney Docket Number

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
xeminer nitlata	Cita No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the flam (book, magazine, journal, sartal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	77
INT "		PECORARI, Piergiiogio, et al, "Synthesis And Biological Activity of Pyrimido [2,1-b] [1,3]Thiazine, [1,3]Thiazino[3,2-a]Purine And [1,2,3]Triazolo[4,5-d][1,3]Thiazino[3,2-a]Pyrimidine Derivatives And Thiazole Analogues (*)", IL Farmaco, 46 (7,8), 1991; pp 899-911	
	1	DE MELO, S. J., et al, "5-flouro (3H) pyrimidine-4-ones: synthese, reactivite et proprietes pharmacologiques", Ann. Pharmaceutiques françaises, 1992, 50, n 1, pp 39-51:	
	1	Chem. Abstr. 1992; 117; pp 143023e- COPY TO FOLLOW De Melo et. al.	
V		FASKHUTDINOW, et al, Kim. Farm. Zh. 1988; 22(5); pp 557 - G OPY TO FOLLO W	
	~	Chem. Abstr. 1988; 109; pp 162901r-COPY TO FOLLOW Faskhutdino V et.al	P.
114	V	TOZKOPARAN, Birsen, et al, "Condensed Heterocyclic Compounds: Synthesis and Antiinflammatory Activity of Novel Thiazolo[3,2-a]pyrimidines", Arch. Pharm. Pharm. Med. Chem. 331, (Weinheim, Germany): 1998; pp 201-206	
		-	
		·	
			L

Examiner Date 16 Signature Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not clistion is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English tanguage Translation is attached.

ORIGINALLY FILED

Please type a plus sign (+) inside this box -> +

Picesse type a plus sign (+) instrict this box

+ Approved for use through 10/31/2002 OMB 0851-0031

U.S. Petent and Tradement Office: U.S. CEPARTMENT OF COMMERCE

Under the Progressor Reduction Act of 1995, no persons are required to respond to a collection of information unless a contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as niony sheets as necessary)

Sheet of

Filing Date February 8, 2002 First Named inventor Richard Dennis Dyer, et al Group Art Unit Unknown		
Application Number	10/071032	
Filing Date	February 8, 2002	
First Named Inventor		1,0
Group Art Unit	Unknown	
Examiner Name	Unknown	
Attorney Docket Number	A0000425-01-CFP	

Examiner Che Initials' No.1	U.S. Patent Document Num-er Rind Code* (of Enour)	Name of Patentee or Applicant of Cited Document Naka, et al Furuya, et al Peterson, Jr., et al Bender, et al	Date of Publication of Clad Document MM-00-YYYY 01/21/1992 10/06/1998 09/07/1999	544/278 546/114 514/255
	5, 82,838 5, 17,819 5, 48,780	Furuya, et al Peterson, Jr., et al	10/06/1998 09/07/1999	646/114
	5. 48.780	Peterson, Jr., et al	09/07/1999	546/114
TNT V				モリリフンツ
TNT V	6.∵38.243	Bender, et al	12/29/1000	フリノメララ
	l		12/20/1999	514/422
				
				·
				
	 		 	
	 			RECEIVED
			 	
				AUG O 1 ZUUZ
	[]			

			ξ	FOR	IGN PATENT DOCUMENT	3		
Examiner Initials	Cão 1 to.1	Office ³	Foreign Patent Docum Number ⁴	nent Kind Codes (If known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Unes, Where Ratevant Passages or Retevant Floures Appear	74
TNA	J	WO	95/35296		Takatani, et al	12/28/1995		
4	V	WC.	01/63244 A1		Chen, et al	08/30/2001		
	V	EP	0 404 525 B1		Naka, et al	05/15/1996		Γ
	1/	GB	2 097 396 A		Seivaku, et al	11/03/1982		
INT	V	DE	41 37 437 A1		Furrer, et al	05/19/1993		
	V	EP	0 404 525 A		Naka et al	12/27/1990	- Duolitat	Ł
								L
								<u> </u>
						<u> </u>		1

Examiner Signature	allon	Date Considered	5/12/04
Signaturs		100.000	

*EXAMINER: Initial if refu-ince considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy if this form with next communication to applicant.

Burden Hour Statement: Titls form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademerk Office, Washington, DC 20231. DO NOT SERD FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.:). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. *Applicant is to : lace a check mark here if English language Translation is attached.

ORIGINALLY FILED

Attorney Docket Number

Please type a pb:s sign (+) in-bia this box -> +

of

PTO/S8/088 (08-00) U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

A0000425-01-CFP

RECEIVED

AUG 0 1 2002

Under the Papa. onk Raduct of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete If Known Substitute for form 14 38/PTO 10/071032 Application Number INFORMATION DISCLOSURE February 8, 2002 Filing Date Richard Dennis Dyer, et al First Named Inventor STATEME IT BY APPLICANT Unknown **Group Art Unit** Unknown (use as namy sheets as necessary) Examiner Name

Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher, city and/or country where published. Exeminer Cita Intials No 1 MO: (ANA, John, et al, "The design of selective non-substrate-based matrix metalloproteinase inhibitors", Curr at Opinion in Drug Discovery & Development, 2000; 3(4), pp 353-361 CLA . K. Ian, et al, "Matrix metalloproteinase inhibitors in the treatment of arthritis", Current Opinions in Anti-inflammatory & Immunomodulatory Investigational Drugs, 2000; 2(1), pp 16-25 CHE. , James, et al, "Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design", J. Am. Chem. Soc., 2000, 122; pp 9648-3654 . DER /ENT ABSTRACT, 96-068630/07, "New fused imidazole cpds. - possess inhibitory activity of adhe ion molecule expression (Eng.)", 19966.

anter :sclerosis" 1993 DEL MENT ABSTRACT, 91-001547/01, "New sulphur-Contg. fused pyrimidine cpds. - are endothelin and inter: akin inhibitors for treatment and prevention of myocardial infarction, auto:immune diseases, etc." DER TENT ABSTRACT, 93271 E/44, "Cyclised pro-form of 5-flouro-uracil derivs. - are orally admi "stered antitumour agents without side effects of parent" KAU , Ravinder, et al, "2-14C-1-Allyl-3,5-diethyl-6-chlorouracil II: Isolation and Structures of the Major Sulfu-Free and Three Minor Sulfur-Containing Metabolites and Mechanism of Biotransformation", Journal of P: maceutical Sciences, Vol. 71, No. 8, August 1982; pp 897-900 KAU., Ravinder, et al, "Structure of a novel sulphur-containing metabolite of Acturacil (1-al -1-3,5-dicthyl-6-chlorouracil)", Xenobiotica, 1982, Vol. 12, No. 8; pp 495-498 , Von R., et al. "Identfizierung eines dritten S-haltigen Metaboliten von 1-Al' 1-3,5-diethyl-6-chloruracil und Bildungsmechanismus der SCH - Metaboliten", Arz. in.-Forsch /Drug Res., 1982; 32(1)(6); pp 610-612 .

DE: ../ENT ABSTRACT, 93-168431/21, "New Thiazolo-pyrimidine disone derivs. for treating

OFFICE OF PETITIONS Examine: Dale Considered Signature

BR: /N, ct al, "The Synthesis of Some 1-Substituted Cytosine and Uracil Derivatives", J.

EXAMINER: Initial if refer

1977. pp 2335-2391


tra considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy to his form with next communication to applicant.

Burden Hour : tatement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are quired to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademant Office, Washington, DC 20231.

DO NOT SEND FEES OR DIPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



¹ Unique citati in designatio: number, ² Applicant is to place a check mark here if English tanguage Translation is attached.



COPY OF PAPERS ORIGINALLY FILED

Please type a plus sign (+) inside this box + + Approved for use through 10/31/2002, OMB 0531-0031

U. C. Refer and Tradement Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Cubality	te for form 1449B/PTC			Complete If Known			
				Application Number	10/071032		
INFO	DRMATION	Di	SCLOSURE	Filing Date	February 8, 2002		
AT2	TEME: IT D	V A	PPLICANT	First Named Inventor	Richard Dennis Dyer, et al		
, 317	TEME. TI	,, ,	u i Lioziti	Group Art Unit	Unknown		
À	(use as many sh	neets e	is necessary)	Examiner Name	Unknown		
heet	3	of	3	Attorney Docket Number	A0000425-01-CFP		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ⁶	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(a), volume-lesue number(a), publisher, city and/or country where published.	7
W.	V	PECCRARI, Piergiiogio, et al, "Synthesis And Biological Activity of Pyrimido [2,1-b] [1,3]Thiazine, [1,3]Thiazino[3,2-a]Pyrimidine Derivatives And Thiaz ole (*)", IL Farmaco, 46 (7,8), 1991; pp 899-911	
	V	DE N ELO, S. J., et al, "5-flouro (3H) pyrimidino-4-ones: synthese, reactivite et proprietes pharmacologiques", Ann. Pharmaceutiques francaises, 1992, 50, n 1, pp 39-31, "	
	V	Chem. Abstr. 1992; 117; pp 143023e - COPY TO FOLLOW	
	V	PASKHUTDINOW, et al, Kim. Farm. Zh. 1988; 22(5); pp 557 - COPY TO FOLLOW	1
		Cher t. Abstr. 1988; 109; pp 162901r - COPY TO POLLOW-	1
NY	/	TOZ:KOPARAN, Birsen, et al, "Condensed Heterocyclic Compounds: Synthesis and Antiinflammatory Activity of Novel Thiazolo[3,2-a]pyrimidines", Arch. Pharm. Pharm. Med. Che. 1. 331, (Weinheim, Germany); 1998; pp 201-206	
·			
		·	
-		RECEIVED	\perp
		AUG 0 1 2007	
		OFFICE OF PETITIONS	

Examiner Date Signature Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

(Rev. 2-32)	1449	C	S. D OM: RAD	ME	RCE	PA.	TE	NT A		D	ATTY. DO	OCKET NO).	SERIA 10/07	L NO. 1,032	Euro
SUPPLEM:	ENTA TATE	ME)	FOR IT B	MA Y A	TIO PPI	JC.)ISC ANT	LO	SU	RE		Dennis Dy	er, et al.			
	(Use	severa	I shee	ts if	nece	ssary) —				FiLING D	ATE y 08, 2002		GROU 1624	P	
EVANDED.				ME	NT.	NI 11	AD.	_	<u>U.</u> S	S. PA	ľ	DOCU	MENTS	CLASS	SUBCLASS	FILING
EXAMINER INITIAL		Т		ME	1		м <i>Б</i> .	EK	т-	DA					-	IF APPRO
	\vdash	H	+	H	Н	+	\dagger	+	t	-	-					
		П	1	L		1	1	1	I							
	╌	Н	╁	\vdash	Н	+	+	╁	╀	├	+					
			1	L			1	1								
			\perp	L	Ш		\perp	Т.	L	<u> </u>						
							F	ΟĮ	RE	IGN	PATE	NT DO	CUMEN	TS		
		D	o cu	ME	TNE	NU	MB	ER		DAT	E	COU	NTRY	CLAS	S SUBCLA	SS TRANS
TNT	1	Т	To	To	Ιo	9	4	8	5	02/24	00 WO			-		_ TES
1	ブ	\top	0	ī	ī	2	6	1	ī	+	01 WO					
	1	\perp	0	2	3	4	7	2	6	05/02	02 WO					
		_	0	2	3	4	7	5	3	┺—-	02 WO					
	1	+	0	9	┰	5	9	6	3	08/18						
TNI	4	+	+-	1	3	8	6	8	0	10/04	OI EP					
		+	+		+	┝	┢		H	 		** * * *				
	\top	\top	1	T		Τ										
			Ι	oxdot												
-		+	↓_	ļ	╀-	_	_	L	L	┞					<u> </u>	
		4-	╃-	_	├	┝	-	┞	-							+-
			⊥	_	<u></u>	L		L_	<u> </u>	<u> </u>	<u> </u>					
0	TH	ER	D?	C	U	ИF	îN	TS	6 0	Inclu	ding A	uthor.	<u> Fitle, Dat</u>	e. Pertin	ent Page	es. etc)
			Ť۱						_							
			1 1											•		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not it conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DC CUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PL/CED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOCKET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.

PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number.

Substitute for form 1449/PTO

AUS 2 5 2004.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 10/071,032 Filing Date February 8, 2002 First Named Inventor Richard Dennis Dyer

Art Unit 1624

Examiner Name Tamthom Ngo Truong Attorney Docket Number A0000425-01-CFP

(Use as many sheets as necessary) Sheet of

subclass Class U.S. PATENT DOCUMENTS Name of Patentee or Pages, Columbs, Lines, Where Refevent Passages of Relevant Figures Appear Examine Document Number Publication Date Initials* No. MM-DD-YYYY Applicant of Cited Document Number-Kind Code² (7 most) US- 2003/0004172 TNT V 01-02-2003 Harter, et al 514 /260.1 US- 2003/0078276 04-24-2003 Andrianjara, et al 514 766+ us- 2002/0193377 12-19-2002 Andrianjara, et al V US- 2003/0144274 1/ 07-31-2003 Bunker, et al 1223,2 US-2003/0130278 V 07-10-2003 Gaudilliere, et al 1228,5 US- 2003/0216402 11-20-2003 Gaudilliere, et al. 514 /251 V US- 2004/0006077 01-08-2004 Gaudilliere, et al 514/227.8 US- 2004/0063673 V 04-01-2004 Johnson 514/114 US- 2004/0034054 02-19-2004 Wilson <u>514/301</u> 514/243 US- 2004/0038973 02-26-2004 Nahra et al. US- 2004/0039012 02-26-2004 Wilson 514/301 US-2004/0038994 Wilson 02-26-2004 514/260. us-2004/0043991 03-04-2004 Picard et al. 514/222.8 US-4,419,356 12-06-1983 Debarre et al. 514/259.2 US-4,421,914 12-20-1983 Okamura et al. 544/278 us-4,383,996 05-17-1983 Oba et al. 514/259.2 us-4,302,585 Wei et al. 11-24-1981 544/247 US-10/739,261 Filed 12-18-2003 Bunker et al.

	FOREIGN PATENT DOCUMENTS								
Examiner Initiats*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Γ			
		Country Code ³ "Number * "Kind Code ³ (# known)	MIM-DD-YYYY			T			
TNT	\sqrt{f}	WO 02/064599	08-22-2002	Dyer et al					
1		WO 02/064598	08-22-2002	Harter, et al		Г			
	\	WO 02/064080	08-22-2002	Andrianjara, et al		П			
	V	WO 02/064572	08-22-2002	Andrianjara, et al					
		WO 03/032999	04-24-2003	Bunker et al.					
TVT		WO 03/033478	04-24-2003	Gaudilliere et al.					

Exeminer	310 - 1	Date	
Signature		Considered	1 11-16-04
			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-latter code (WIPO Standard ST.3), 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sents) number of the patent document. 'Nind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST.18 If possible. 'Applicant is to place a check mark here if English language Translation is attached.

Transation is suscised.

Transation is inscribed.

Transation is insured as suscised.

Transation is insured by 37 CFR 1.97 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandris, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandris, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031 U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

o a collection of information unless it contains a valid QMB control number. the Paperwork Reduction Act of 1995, no persons are required to respon

Substitute for form 1449/PTO

AUS 7 5 7004

TATA TRAVEN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known						
Application Number	10/071,032					
Filing Date	February 8, 2002					
First Named Inventor	Richard Dennis Dyer					
Art Unit	1624					
Examiner Name	Tamthom Ngo Truong					
Attament Dealest Mamban	A0000426 01 CED					

Exeminer	C#a	Document Number	U. S. PATENT D Publication Date	Name of Patantee or	Page Cohimne Lines Where
initials*	Ctbs No.1	Number-Kind Code ^{2 (7 kmm)}	MON-OD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pessages or Relevant Figures Appear
		US-	 		
	-	US-	+		
		US-		······································	
		US- ·	 		
		US-			
		US-			
		US-			
		US-	1		
		US-			
	٠.	US-		•	
		US-)	·
		US-			
		US-			
		US-			
		US			
		US			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	70			
		Country Code ³ "Number ⁴ "Kind Code ⁶ (<i>E known</i>)	MM-DD-YYYY						
TNT	V	WO 03/076417	09-18-2003	Gaudilliere et al.					
	V	WO 2004/000322	12-31-2003	Gaudilliere et al.					
	1/	WO 2004/014384	02-19-2004	Johnson		Γ			
	V	WO 2004/014375	02-19-2004	Wilson					
1	l i/	WO 2004/014365	02-19-2004	O'Brien et al.					
TNY	V	WO 2004/014908	02-19-2004	Wilson					

Examiner Signature	Mom	Date Considered	11/6/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.usnto.nov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Cfices, P.O. Box 1450, Asoxandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

PTO/S8/08A (08-03)

Approved for use through 07/31/2008. QMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMS control number.

Substitute for form 1449/PTO

AUS 2 5 2004

THE TRACEMAR

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many aheats as necessary)

Complete if Known					
Application Number	10/071,032				
Filing Date	February 8, 2002				
First Named Inventor	Richard Dennis Dyer				
Art Unit	1624				
Examiner Name	Tamthom Ngo Truong				
Attament Destrot Number	14 0000436 OL CCD				

			U.S. PATENT	DOCUMENTS	
Examiner Initials*	City No.	Document Number Number-Kind Code ² (Farmer)	Publication Cate MiM-DD-YYYY	Name of Patentee or Applicant of Chad Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	 	US-			
	_	US-	 		
	<u> </u>	US-			
					<u> </u>
		us.			
		US-			
		US-			
		US-			
		US-			
		US-			·
		US-			
		US-			
•		US-			
		NS-			
		US-			
		US-			
		UŞ-			
		ÚS-			
		US-			
		US-			

Examiner Initials*	No.1	Foreign Patent Document Country Code* Number* "Rind Code* (# Innown)	EIGN PATENT DOCI Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pessages	
					Or Relevant Figures Appear	70
TNI	/	WO 2004/014916	02-19-2004	Wilson		
TWT	1	WO 2004/014923	02-19-2004	Picard et al.		
TNÍ	/	WO 96/38434	12-05-1996	Hupe et al.		C
		·				

Examiner Signature	Mom	Date Considered	11/	16/	04

*EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through cliation if not in conformance and not considered, include copy of this form with next communication to applicant. *Applicant's unique citation designation number (aptional). *See Kinds Codes of USPTO Patent Documents at www.uspto.copy or MPEP 801.04. *Enter Office that issued the document, by the two-tester code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection is required by 37 CFR 1.97 and 1.88. The information is required to obtain or retain a benefit by the public which is to like (and by the USPTO to process) an application. Comfidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any commants on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradsmark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patenta, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

PATS TRA

PTO/SB/08B (08-03)

Approved for use through 07/31/2008, CMB 0851-0031
U.S. Peters and Tradement Office; U.S. DEPARTMENT OF CONMERCE
and to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known			
				Application Number	10/071,032		
INFO	DRMATION	N DIS	CLOSURE	Filing Date	February 8, 2002	002	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Richard Dennis Dyer	•	
(Use as many sheets as necessary)				Art Unit	1624		
				Examiner Name	Tamthom Ngo Truong		
Sheet	4	of	4	Attorney Docket Number	A0000425-01-CFP		

e	1 04-	NON PATENT LITERATURE DOCUMENTS	_
xaminer nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
TVT	/	Office Action from 10/264,764 (PC20536A) mailed 6.16.03	
	V	LOVEJOY et al., "Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors", Nature Structural Biology, 1999, Vol. 6, No. 3, pages 217-221.	
	i/	MOY et al., "High-resolution Solution Structure of the Catalytic Fragment of Human Collagenase-3 (MMP-13) Complexed with a Hydroxamic Acid Inhibitor", J. Mol. Biol., 2000, Vol. 302, 671-689	
	/	MITCHELL et al., "Cloning, Expression, and Type II Collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage", J. Clin. Invest., 1996, Vol. 97, No. 3, pages 761-768	
		NEUHOLD et al., "Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) reduces osteoarthritis in mice", J. Clin. Invest., 2001, Vol. 107, No. 1, pages 35-44.	
	1	DAHLBERG et al., "Selective Enhancement of Collagenase-Mediated Cleavage of Resident Type II Collagen in Cultured Osteoarthritis Cartilage and Arrest with a Synthetic Inhibitor that Spares Collagenase I (Matrix Metalloproteinase I)", Arthrit. & Rheum., 2000, Vol. 43, No. 3, pages 673-682	
		BILLINGHURST et al., "Comparison of the Degradation of Type II Collagen and Proteoglycan in Nasal and Articular Cartilages Induced by Interleukin-1 and the Selection Inhibition of Type II Collagen Cleavage by Collagenase", Arthrit. & Rheum., 2000, Vol. 43, No. 3, pages 664-672	
		BILLINGHURST et al., "Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage", J. Clin. Invest., 1997, Vol. 99, No. 7, pages 1534-1545	
		HIROTA et al., "Novel Synthesis of Pyrido[3,4-d]pyrimidines, Pyrido[2,3-d]pyrimidines, and Quinazolines via Palladium-Catalyzed Oxidative Coupling", Heterocycles, 1994, Vol. 37, No. 1, pages 563-570	
70/		PCT International Search Report, PCT/IB02/00313	•

Examiner	11//	Date	1101.0
		1	I NILLIOU
Signature		Considered	11/10/09

*EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

**EXAMINEP: Initial in retarence considered, whether or not clasion is in comormance with MPEP 6US. Draw time strough classion in not in conformance and not considered, include copy of this form with next communication to applicant.

1 Applicant's unique clastion designation number (optional). 2 Applicant is to place a check mark here if English language Translation is stached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confideratelly is governed by 38 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Crief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 2213-1450. DO NOT SEND FEES OR CONPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.